S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
| Published in: | HemaSphere |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968124.64352.6e |
| _version_ | 1850010322241323008 |
|---|---|
| author | Gili Kenet Beatrice Nolan Bulent Zulfikar Bulent Antmen Peter Kampmann Tadashi Matsushita Chur-Woo You Kateryna Vilchevska Catherine N. Bag Azizan Sharif Flora Peyvandi Guy Young Claude Negrier Christian Sussebach Fadi Shammas Shauna Andersson Baisong Mei Kaan Kavakli |
| author_facet | Gili Kenet Beatrice Nolan Bulent Zulfikar Bulent Antmen Peter Kampmann Tadashi Matsushita Chur-Woo You Kateryna Vilchevska Catherine N. Bag Azizan Sharif Flora Peyvandi Guy Young Claude Negrier Christian Sussebach Fadi Shammas Shauna Andersson Baisong Mei Kaan Kavakli |
| author_sort | Gili Kenet |
| collection | DOAJ |
| container_title | HemaSphere |
| format | Article |
| id | doaj-art-2a45dff57f9c4ff2bedf75d75d9983b0 |
| institution | Directory of Open Access Journals |
| issn | 2572-9241 |
| language | English |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| spelling | doaj-art-2a45dff57f9c4ff2bedf75d75d9983b02025-08-20T00:44:33ZengWileyHemaSphere2572-92412023-08-017e643526e10.1097/01.HS9.0000968124.64352.6e202308003-00205S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXISGili Kenet0Beatrice Nolan1Bulent Zulfikar2Bulent Antmen3Peter Kampmann4Tadashi Matsushita5Chur-Woo You6Kateryna Vilchevska7Catherine N. Bag8Azizan Sharif9Flora Peyvandi10Guy Young11Claude Negrier12Christian Sussebach13Fadi Shammas14Shauna Andersson15Baisong Mei16Kaan Kavakli171 The National Hemophilia Centre, The Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Hashomer, Tel Aviv University,, Tel Aviv, Israel2 Children’s Health Ireland at Crumlin, Dublin, Ireland3 Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute,, Istanbul, Turkey4 Department of Pediatric Hematology/Oncology and Bone Marrow Transplantation Unit, Faculty of Medicine, Acibadem University, Adana Hospital, Adana, Turkey5 Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark6 Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan7 Department of Pediatrics, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea, Rep. of South8 National Children’s Specialized Hospital OHMATDYT, Kyiv, Ukraine9 Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom10 Hospital Sultanah Aminah, Johor Bahru, Malaysia11 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy13 Hemostasis and Thrombosis Center, Cancer and Blood Diseases Institute, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, LA, CA, United States14 Louis Pradel University Hospital, Claude Bernard University Lyon 1, Lyon, France15 Sanofi, Frankfurt, Hessen, Germany16 Sanofi, Montreal, Quebec, Canada17 Sanofi, Cambridge, MA, United States17 Sanofi, Cambridge, MA, United States18 Kaan Department of Haematology, Ege University Faculty of Medicine, Children’s Hospital, Izmir, Turkeyhttp://journals.lww.com/10.1097/01.HS9.0000968124.64352.6e |
| spellingShingle | Gili Kenet Beatrice Nolan Bulent Zulfikar Bulent Antmen Peter Kampmann Tadashi Matsushita Chur-Woo You Kateryna Vilchevska Catherine N. Bag Azizan Sharif Flora Peyvandi Guy Young Claude Negrier Christian Sussebach Fadi Shammas Shauna Andersson Baisong Mei Kaan Kavakli S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_full | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_fullStr | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_full_unstemmed | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_short | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_sort | s303 a phase 3 study atlas ppx to evaluate efficacy and safety of fitusiran in people with haemophilia a or b who have switched from prior clotting factor concentrate or bypassing agent prophylaxis |
| url | http://journals.lww.com/10.1097/01.HS9.0000968124.64352.6e |
| work_keys_str_mv | AT gilikenet s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT beatricenolan s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT bulentzulfikar s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT bulentantmen s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT peterkampmann s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT tadashimatsushita s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT churwooyou s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT katerynavilchevska s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT catherinenbag s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT azizansharif s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT florapeyvandi s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT guyyoung s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT claudenegrier s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT christiansussebach s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT fadishammas s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT shaunaandersson s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT baisongmei s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT kaankavakli s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis |